

3rd Annual World ADC Awards winners announced

The World ADC Awards reward the innovation, leadership, and devotion shown by the best companies, teams, and individuals in the industry.

SAN DIEGO, CALIFORNIA, USA, October 12, 2016 /EINPresswire.com/ --Wednesday October 12 2016 San Diego, CA

3rd World ADC Awards winners announced.

World ADC is pleased to announce the winners of the 3rd Annual World ADC Awards.



The World ADC Awards reward the innovation, leadership, and devotion shown by the best companies, teams, and individuals in the industry. Across nine categories the Awards exist to



Every year the judges are impressed with the level of innovation and scientific breakthroughs that these companies are driving. This year is no exception."

Fiona Mistri, Program Director, World ADC

recognize the extraordinary endeavor's, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today. The Awards are sponsored by Abbvie and Pfizer.

The Awardees were shortlisted by over 1500 nominations and then scientific proposals from each were evaluated by our Judging panel.

Fiona Mistri, Program Director, World ADC San Diego stated:

"Every year the judges are impressed with the level of

innovation and scientific breakthroughs that these companies are driving. This year is no exception and we are delighted to see the calibre and quantity of entries – showing the growing momentum and advances being made within the industry.

The 2016 winners are:

Best ADC Platform Technology Winner – Fleximer (Mersana Therapeutics) Runner Up – Bicycles (Bicycle Therapeutics)

Most Promising Clinical Candidate

Winner – Rovalpituzumab tesirine (Abbvie-Stemcentrx) Runner Up – MEDI4276 (MedImmune)

Best Contract Manufacturing (CMO) Provider Winner - BSP Pharmaceuticals Runner Up - Piramal

Best Contract Research (CRO) Provider Winner - Abzena

Best New Drug Developer sponsored by Pfizer Winner - ADC Therapeutics Runner Up – Mersana Therapeutics

Best Publication 2015

Winner - Saunders et al., A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med., 2015.

Runner Up - van Geel et al., Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N_Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates; Bioconj. Chem., 2015.

Best Poster sponsored by Abbvie

Winner - Computational Exploration of Mechanistic Determinants of ADC Pharmacokinetics Using QSP Modeling Strategies; AK Wilkens et al.

Runner Up - Discovery and Characterization of ADCs with a Novel Mode of Action; G Piizzi et al.

Individual Input to the Field 2015/2016 Winner - David Thurston Runner Up - Scott Dylla

Long Standing Contribution Winner - John Lambert

The Award winners were announced at an Awards Ceremony on October 12 at the Marriott Marquis San Diego, as part of the 7th Annual World ADC San Diego.

Scott Dylla, VP R&D and CSO, Abbvie-Stemcentrx remarked: "Support of these awards represents AbbVie's dedication to and recognition of innovation in Antibody Drug Conjugate research around the world.

These awards, which acknowledge peer-recognized notable work and contributions to the ADC field are aligned with our passion for developing novel therapies to address the world's most difficult health problems and providing a remarkable impact on people's lives."

For more information about the World ADC Awards visit http://worldadc-awards.com/

About World ADC San Diego:

Focused on ADCs and crafted with the field's thought-leaders, World ADC is the industry's definitive forum for learning and networking.

About Abbvie:

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visitwww.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

About Pfizer:

Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.

Jenny Barlow World ADC San Diego +44 20 3862 7310 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.